• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
TREAT-NMD

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Conference

Charcot-Marie-Tooth

Home / Resources and Support / Neuromuscular Disease Information / Charcot-Marie-Tooth

What is Charcot-Marie-Tooth disease?

Charcot-Marie-Tooth disease (CMT) is named after the three neurologists who first described the condition in 1886.  The other term commonly used to describe the condition is hereditary motor and sensory neuropathy (HMSN). This name describes the two primary features of this condition: it is hereditary (passed on in the genes from parent to child) and it affects the motor and sensory peripheral nerves. CMT is not in fact a single disorder but a group of conditions that share some similarities.

What causes Charcot-Marie-Tooth disease?

Researchers have identified a number of genes in which mutations are known to cause CMT. These mutations usually affect the production of a particular protein in the peripheral nerves, either causing the protein to be faulty or not produced at all which leads to peripheral nerve damage.

CMT is a hereditary disease in which the genetics are very complicated; the disease has different inheritance patterns for different types of CMT. Most sub-types of CMT type 1 are inherited in an autosomal dominant manner – this means that you only need to inherit the faulty gene from one parent to have the condition. CMT X1 is the only exception in the type 1 category: it has X-linked inheritance, which means it is determined by a gene carried on the X chromosome. As males have only one X chromosome, and females have two, males tend to be much more severely affected by CMT X1 than females.

Although most sub-types of CMT type 2 are autosomal dominant, there are a few rare sub-types that are inherited in an autosomal recessive manner. This means that you need to inherit the faulty gene from both parents to have the condition.

What are the signs and symptoms of Charcot-Marie-Tooth disease?

In the more common types of CMT, the first symptoms usually occur in the first decade of life, however, in other types, symptoms may not appear until much later. Many people with CMT have high arched feet (known as pes cavus) which becomes particularly noticeable at the time of the growth spurt associated with puberty. Some people have weakness in their hands, but this does not usually cause symptoms until after the age of 20.

People can experience numbness in their feet and hands and having cold feet is quite common too. Many patients with CMT eventually develop contractures (stiffened joints) that result in deformities of the feet and hands.

How does the disease progress?

The types of CMT which run through the generations are very slowly progressive. It is unusual for people with CMT to lose the ability to walk, although some people – especially when they are older – may need to a walking aid. The severity of the condition is highly variable, but the condition only rarely leads to severe disability.

 

Primary Sidebar

  • Resources and Support
  • Disease Information
    • Neuromuscular Disease Information
    • Becker muscular dystrophy
    • Charcot-Marie-Tooth
    • Congenital muscular dystrophy
    • Congenital myasthenic syndromes
    • Duchenne muscular dystrophy
    • Facioscapulohumeral muscular dystrophy
    • GNE myopathy
    • Limb girdle muscular dystrophy
    • Myotonic dystrophy
    • Myotubular and centronuclear myopathies
    • Spinal muscular atrophy
  • Research Overview
    • Research Overview
    • Gene Therapy Research
    • DMD
      • DMD
      • Gene Therapy for DMD
      • Mutation Specific Approaches
      • Cell Therapy
      • Drug Therapy
  • Standards of Care & Family Guides
    • Care Guides
    • CM Care
    • CMD Care
    • DM Care
    • DMD Care
    • FSHD Care
    • SMA Care
  • Standard Operating Procedures (SOPs)
    • SOP Library
    • MDX Mouse (DMD)
    • GRMD Dog (DMD)
    • CMD Mouse (CMD)
    • SMA Mouse (SMA)
    • SOP Archive
      • MDX mouse (DMD) Archive
      • SMA mouse (SMA) Archive
      • Mouse model (DMD) Archive
  • Social and Ethical issues
    • Social and Ethical Issues
    • Concerns Over Stem Cell Therapy for SMA Type 1 Children
    • Early Access to Medicines in Development
    • Ethical Questions

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

Connect

info@treat-nmd.com
TREAT NMD © 2023
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
    • Back
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
    • Back
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
      • Back
    • The Global Registry Network
      • Members of the Registry Network
      • Back
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
      • Back
    • Education
      • Masterclasses
      • E-learning Platform
      • Endorsement of External Programmes
      • Back
    • Post-Marketing Surveillance
    • Back
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
      • Back
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
        • Back
      • Back
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • FSHD Care
      • SMA Care
      • Back
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
        • Back
      • Back
    • Social and Ethical Issues
    • Back
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Conference
    • Back